Interference of bone marrow CD56⁺ mesenchymal stromal cells in minimal residual disease investigation of neuroblastoma and other CD45⁻/CD56⁺ pediatric malignancies using flow cytometry

Abstract

RCP that were immunophenotypically similar to NBL were identified as CD56⁺ MSCs. As these cells might pose an obstacle to accurate NBL disease assessment by FC, especially MRD, an enhanced NBL-FC protocol is proposed for prospective evaluation.